REGNRegeneron Pharmaceuticals, Inc.

Business Overview Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes prescription biologic medicines, generating revenue primarily from net product sales (e.g., EYLEA HD®, EYLEA®, LIBTAYO®) and from collaboration revenue (notably profit-share economics tied to Dupixent® and other antibodies sold with partners such as Sanofi and Bayer). Market Position Regeneron is a major innovator in antibody-based therapeutics, with durable scale in retina and immunology/oncology supported by integrated R&D and biologics manufacturing; a meaningful portion of earnings is also driven by partnered franchises where Regeneron participates via profit share/royalties rather than booking full end-market sales. Key Segments Regeneron reports one operating segment, encompassing all activities related to the discovery, development, and commercialization of medicines for serious diseases.